Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by VentureGuy24on Jun 24, 2018 9:27am
207 Views
Post# 28220103

Superior PDCs

Superior PDCs

“A team of researchers from Lobachevsky University (Nizhny Novgorod, Russia) headed by Professor Alexei Fedorov, chair of the Organic Chemistry Department, is working to create a new generation of targeted anti-cancer drugs for photodynamic therapy.

Today, there are many ways to fight cancer. The problem is that every case of cancer is unique in its own way, and there is no single winning treatment strategy. Doctors can try to combine different therapies and observe the best response to their combination.

On widely used treatment method is photodynamic therapy. "In this method, a photosensitizer is injected into the bloodstream or applied to the affected area of the skin, and used to destroy tumors. When this molecule is activated by light, a number of chain processes are initiated that result in the death of tumor cells," Fedorov notes.

However, there are some problems associated with the application of this approach. Current photosensitizer drugs have a number of serious advantages, but one significant drawback: The selectivity of their accumulation in tumor tissue is very low. In other words, when these drugs are administered to the patient, they are distributed almost evenly between healthy tissues and those affected by tumors. It is quite obvious that this balance should be shifted toward predominant accumulation in tumors. Current efforts of researchers in many countries are focused on achieving this goal”

Theralase solved that problem!!!

Bullboard Posts